PDCD1 and hepatocellular carcinoma: Combination therapy of anti‐programmed cell death protein‐1 (PD‐1) antibodies and tyrosine kinase inhibitors (TKIs) has significantly improved the prognosis for hepatocellular carcinoma (HCC), but many patients still have unsatisfactory outcomes.